Stay updated with breaking news from Alanh Auerbach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head and neck squamous cell carcinoma (Clinicaltrials.gov identifier NCT04555837)...
The FDA has granted an orphan drug designation to alisertib (MLN8237) for the treatment of patients with extensive-stage small cell lung cancer.
HC Wainwright restated their buy rating on shares of Puma Biotechnology (NASDAQ:PBYI – Free Report) in a research note released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $8.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the stock. StockNews.com started coverage on shares of […]
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A, for the treatment of patients...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to alisertib, a selective, small-molecule, orally...